OncoMatch/Clinical Trials/NCT06610825
Castrate Resistant Prostate Cancer Enhertu Therapy
Is NCT06610825 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Enhertu for prostate cancer metastatic.
Treatment: Enhertu — Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Prostate Cancer
Biomarker criteria
Required: HER2 (ERBB2) any tested (testing required; no eligibility threshold specified)
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: androgen deprivation therapy
Documented progression on androgen deprivation
Must have received: novel hormonal agent
Documented progression on...novel hormonal agents
Cannot have received: HER2-targeted therapy
Previous exposure to HER2 targeted therapy
Lab requirements
Blood counts
Adequate Organ and Bone Marrow function; Adequate Blood Clotting function
Kidney function
Adequate Renal function
Liver function
Adequate Hepatic function
Cardiac function
LVEF at least 50%
Adequate Blood Clotting function; Adequate Organ and Bone Marrow function; Adequate Renal function; Adequate Hepatic function; LVEF at least 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington DC VAMC · Washington D.C., District of Columbia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06610825 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior HER2-targeted therapy disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 any tested is a required biomarker for enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify